Prudential PLC Sells 21,204 Shares of Pfizer Inc. (NYSE:PFE)

Prudential PLC trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 3.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 525,317 shares of the biopharmaceutical company’s stock after selling 21,204 shares during the quarter. Prudential PLC’s holdings in Pfizer were worth $13,937,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in PFE. Unison Advisors LLC boosted its position in Pfizer by 1.4% during the fourth quarter. Unison Advisors LLC now owns 88,978 shares of the biopharmaceutical company’s stock valued at $2,361,000 after buying an additional 1,266 shares during the period. Wescott Financial Advisory Group LLC boosted its holdings in Pfizer by 5.6% during the 4th quarter. Wescott Financial Advisory Group LLC now owns 16,381 shares of the biopharmaceutical company’s stock valued at $435,000 after acquiring an additional 864 shares during the period. Foundry Partners LLC bought a new position in Pfizer during the 4th quarter worth approximately $20,996,000. Huber Capital Management LLC increased its stake in Pfizer by 142.4% in the 4th quarter. Huber Capital Management LLC now owns 488,288 shares of the biopharmaceutical company’s stock worth $12,954,000 after purchasing an additional 286,842 shares during the period. Finally, Uniting Wealth Partners LLC bought a new stake in Pfizer in the fourth quarter valued at approximately $725,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of several analyst reports. UBS Group decreased their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Bank of America reissued a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Truist Financial lowered their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Price Performance

PFE stock opened at $22.99 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market capitalization of $130.39 billion, a price-to-earnings ratio of 16.31, a PEG ratio of 0.64 and a beta of 0.61. The firm has a 50 day moving average price of $25.87 and a 200-day moving average price of $26.76. Pfizer Inc. has a 52-week low of $22.95 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the previous year, the company posted $0.10 earnings per share. The company’s revenue for the quarter was up 24.7% compared to the same quarter last year. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.06% of the stock is currently owned by insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.